About me
Dun is a diagnostics and regulatory expert with unique experience across pharma, diagnostics, and government. At Eli Lilly, He provides critical strategic and tactical guidance, interpretation, and assessments on diagnostic regulations globally. He coordinates, plans, and executes diagnostic regulatory engagements with health authorities to support successful clinical trials, product approvals, and product launches. Previously, as an FDA lead reviewer, he organized and led regulatory reviews of companion diagnostics for cancer drugs and other oncology tests. He had also been a lab director, entrepreneur, and test developer. Passionate about advancing precision medicine, he strives to improve patient care through regulatory innovation.
